Bausch + Lomb's BL1332 misses primary endpoint in Phase 2 ocular pain trial
BLCO•BL1332 missed its primary pain-relief endpoint in a Phase 2 trial after photorefractive keratectomy surgery, though both doses showed numerically greater pain relief than vehicle and exploratory findings suggested faster corneal healing.




